

Collaborative Working Project executive summary

Project title	Barts NHS Trust & Sanofi Atopic Dermatitis Patient Identification and Treatment Optimisation Collaborative Working Project
Partner organisation/s	Barts Healthcare NHS Trust – The Royal London Hospital, 80 Newark Street, London, E1 2ES Sanofi – 410 Thames Valley Park Drive, Reading, Berkshire, RG6 1PT
Project rationale	To help identify patients with moderate to severe atopic dermatitis and ensure that they are assessed in clinic and their treatment is reviewed and optimised
Project period	Q3 2026 to Q3 2027
Project objectives	The main objective of this project is to develop algorithms that will help the identification of patients with moderate to severe AD who are uncontrolled and may benefit from an intervention or a change of therapy. Patient benefits: - Streamlined identification of patient needs for therapy optimisation - Potential reduction in number of hospital visits due to reduced monitoring requirements if commenced on a biologic therapy NHS benefits: - Reduction in uncontrolled atopic dermatitis patients - Potential diminution on mandatory monitoring for atopic dermatitis patients (for patients being put on a biologic treatment) more efficiency in service delivery through better patient control requiring less review - Review of patients who might have been “lost in the system” (i.e. not seen by the dermatology team for a long period of time) - The potential for further service enhancements through their project experience - Support and enhance the skills of the Barts NHS Trust dermatology team in patient data recording, ensuring alignment with best practices to facilitate potential future data-related projects. - Benefit for administration staff regarding overall workload Sanofi Benefits:

	- Improved reputation with relevant NHS organisations across the BARTS Trust within the dermatology space. - Greater clarity around the development of tools to aid identification of uncontrolled atopic dermatitis patients so that we can potentially tailor offerings in the future. - Potential increased use of Sanofi treatments, in line with local and national guidelines because of increased patient identification - Understanding of how working with the NHS can support alignment and co-ordination of dermatology policies and action plans. The project is being completed by collating resources of approximately £23,000 (Sanofi 45% : NHS 55%)
Contact details	Sanofi Paul Naish, Head of Market Access GB-patientaccess@sanofi.com Barts Health Care NHS Trust Dr Margo Gkini Consultant Dermatologist maria-angeliki.gkini@nhs.net

CERTIFICATE FOR NON-PROMOTIONAL ITEMS (PMCPA)

Version: 2 . 0

Document Number: MAT-XU-2603241

Document Name: Barts Collaborative Working Project Executive Summary

Country: Great Britain Northern Ireland

Product: General Dermatology

Material Type: Institutional/Partnership Activities

Material Intent: Non-Promotional

Certification Type: Certification

Audience: General Public Healthcare Professionals Internal Employees Payers

Additional Audience:

Intended Use: External Use

Method of Dissemination: Pro-active

Material Owner: Gary Solomons

I have examined the final form of the material and in my belief it is in accordance with the requirements of the relevant regulations relating to advertising and this Code, and is a fair and truthful representation of the facts.

Role	Signature
Ciara O'brien - Medical	Date: 09-Sep-2026 19:12:50 GMT+0000